Zymergen Investors Win Final OK Of $125M IPO Deal
Investors in the now-defunct biotechnology company Zymergen received final approval of their $125 million deal ending claims that the company misled shareholders ahead of its initial public offering, while plaintiffs' attorneys also...To view the full article, register now.
Already a subscriber? Click here to view full article